Third Rock Ventures

Third Rock Ventures company information, Employees & Contact Information

We discover, launch and build great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine – where transformational science meets operational reality – providing the best opportunity to make a dramatic difference in patients’ lives. THE THIRD ROCK TEAM Our team has a proven record of translating disruptive technologies into valuable business enterprises. Working closely with leading scientific and business visionaries as well as industry partners, we identify opportunities to change the future of medicine and rigorously vet those ideas through our discovery process to develop the vision, strategy and plan needed to succeed. A FORMULA FOR INNOVATION We only invest in the best of those ideas. We are actively involved in the early stages of our companies’ development, typically serving as members of the founding management teams, to build a strong foundation, put in place the right people and culture, and set the companies on a path to scientific and operational excellence. We believe in the companies we launch and make big initial investments, often complemented by strategic alliances, to enable our companies to advance life-changing therapies, devices and diagnostics. By creating value for patients, we create value for our investors.

Company Details

Employees
116
Founded
-
Address
29 Newbury St., 3rd Floor,united States
Phone
(415) 766-3600
Email
in****@****res.com
Industry
Venture Capital And Private Equity Principals
NAICS
Miscellaneous Intermediation
Keywords
Boston.
HQ
Boston, MA
Looking for a particular Third Rock Ventures employee's phone or email?

Third Rock Ventures Questions

News

Synnovation to Present SNV1521 (PARP1) Phase 1 Study Results at the European Medical Oncology (ESMO) Congress 2025 and Announces Clinical Collaboration with DualityBio to Evaluate the Combination of SNV1521 with Duality’s HER3 ADC, DB-1310 - The AI Journal

Synnovation to Present SNV1521 (PARP1) Phase 1 Study Results at the European Medical Oncology (ESMO) Congress 2025 and Announces Clinical Collaboration with DualityBio to Evaluate the Combination of SNV1521 with Duality’s HER3 ADC, DB-1310 The AI Journal

Synnovation Therapeutics Announces the Appointment of Rafael G. Amado, M.D., to Its Board of Directors - Business Wire

Synnovation Therapeutics Announces the Appointment of Rafael G. Amado, M.D., to Its Board of Directors Business Wire

Selected Aspects of the Neuroimmunology of Cell Therapies for Neurologic Disease - Neurology® Journals

Selected Aspects of the Neuroimmunology of Cell Therapies for Neurologic Disease Neurology® Journals

Third Rock Ventures Promotes Andrea van Elsas, Ph.D., to Partner - citybiz

Third Rock Ventures Promotes Andrea van Elsas, Ph.D., to Partner citybiz

Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors - Business Wire

Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors Business Wire

'Third Rock forever': Firm's latest $1.1B funding round will create 10 new biotechs - Fierce Biotech

'Third Rock forever': Firm's latest $1.1B funding round will create 10 new biotechs Fierce Biotech

CARGO Therapeutics Raises $200 Million in Oversubscribed, - GlobeNewswire

CARGO Therapeutics Raises $200 Million in Oversubscribed, GlobeNewswire

New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD - Neurology® Journals

New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD Neurology® Journals

PanOptica Raises $30 Million in Series A Financing and Licenses Lead Compound for Development as Topical Treatment of AMD - PR Newswire

PanOptica Raises $30 Million in Series A Financing and Licenses Lead Compound for Development as Topical Treatment of AMD PR Newswire

Third Rock Ventures Becomes Founding Partner for Project Onramp National Expansion - Business Wire

Third Rock Ventures Becomes Founding Partner for Project Onramp National Expansion Business Wire

Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521, a PARP1 Selective Inhibitor for the Treatment of Solid Tumors - Business Wire

Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521, a PARP1 Selective Inhibitor for the Treatment of Solid Tumors Business Wire

Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells to Treat Serious Autoimmune and Inflammatory Diseases - Business Wire

Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells to Treat Serious Autoimmune and Inflammatory Diseases Business Wire

Top Third Rock Ventures Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant